Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Clopidogrel and Response Variability Investigation Study 2

Phase 3

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: clopidogrel

First Posted Date: 2009-01-14

Last Posted Date: 2012-12-11

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 109

Registration Number: NCT00822666

Locations: 🇫🇷
Hopital la Pitié-Salpétrière Institut de cardiologie, Paris, France

COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke

Phase 4

Completed

Conditions: Stroke

Interventions: Drug: Clopidogrel
Drug: Clopidogrel placebo
Drug: Aspirin

First Posted Date: 2008-12-24

Last Posted Date: 2014-02-28

Lead Sponsor: Sanofi

Target Recruit Count: 358

Registration Number: NCT00814268

Locations: 🇰🇷
Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of

Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)

Phase 4

Completed

Conditions: Platelet Aggregation Inhibitors
Coronary Heart Disease

Interventions: Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2008-11-27

Last Posted Date: 2022-02-24

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 682

Registration Number: NCT00799396

Locations: 🇺🇸
Amish Research Clinic, Lancaster, Pennsylvania, United States

Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects

Phase 4

Completed

Conditions: Migraine

Interventions: Drug: Clopidogrel

First Posted Date: 2008-11-27

Last Posted Date: 2019-02-26

Lead Sponsor: Laval University

Target Recruit Count: 220

Registration Number: NCT00799045

Locations: 🇨🇦
Hopital Laval, Quebec, Canada

Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease

Early Phase 1

Completed

Conditions: Peripheral Vascular Diseases

Interventions: Drug: Placebo
Drug: G-CSF
Drug: Aspirin
Drug: Clopidogrel

First Posted Date: 2008-11-25

Last Posted Date: 2015-04-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 32

Registration Number: NCT00797056

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)

Not Applicable

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Clopidogrel

First Posted Date: 2008-10-29

Last Posted Date: 2018-09-13

Lead Sponsor: North Texas Veterans Healthcare System

Target Recruit Count: 167

Registration Number: NCT00781573

Locations: 🇺🇸
Dallas Veterans Hospital, Dallas, Texas, United States
🇬🇷
The Onassis cardiac Surgery Centre, Athens, Greece
🇮🇳
Escorts Health Institute & Research Centre Ltd, New Delhi, India

Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers

Phase 4

Completed

Conditions: Gastroduodenal Ulcer

Interventions: Drug: Placebo
Drug: Naproxen
Drug: Aspirin
Drug: Clopidogrel
Drug: Celecoxib

First Posted Date: 2008-10-23

Last Posted Date: 2008-10-23

Lead Sponsor: Research Associates of New York, LLP

Target Recruit Count: 125

Registration Number: NCT00778193

Locations: 🇺🇸
Research Associates of New York, New York, New York, United States

Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation

Phase 4

Conditions: Coronary Artery Disease
Atrial Fibrillation

Interventions: Drug: aspirin
Drug: clopidogrel
Drug: oral anticoagulation

First Posted Date: 2008-10-21

Last Posted Date: 2016-08-30

Lead Sponsor: Deutsches Herzzentrum Muenchen

Target Recruit Count: 614

Registration Number: NCT00776633

Locations: 🇩🇪
Deutsches Herzzentrum München, Munich, Germany
🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇪
1. Medizinische Klinik, Klinikum rechts der Isar, München, Germany